Expanding Horizons: Crown Bioscience’s New North Carolina Facility Offers Greater Choice, Speed, and Compliance

In the fast-paced world of translational oncology, pharmaceutical developers face a relentless challenge: how to move programs from the laboratory to the clinic faster without compromising on quality or regulatory standards. At Crown Bioscience, we understand that while proximity is a benefit, it is not the only metric for success. For our partners, speed is critical, and compliance is non-negotiable.

That is why we have strategically expanded our footprint, establishing a premier facility in North Carolina designed to bring world-class Patient-Derived Xenograft (PDX) services to the East Coast of North America. This state-of-the-art site ensures that clients have seamless, compliant, and rapid access to the scientific rigor they expect from Crown Bioscience.

Delivering What Matters: Speed and Compliance

We recognize that drug development timelines are tight. Our clients need partners who can execute studies with precision, ensuring that the data generated is not only fast but robust and fully compliant with global standards.

Our North Carolina facility was built with this dual mandate at its core. By establishing a strong presence on the East Coast of the United States, we are providing our partners with the choice of where to conduct their studies. Whether a project necessitates local proximity to streamline logistics or simply requires additional capacity to accelerate your timelines, this new facility ensures that your research never hits a bottleneck.

At Crown Bioscience, we are committed to giving our clients options, ensuring that study planning is driven by scientific needs and logistical efficiency rather than capacity limitations. No matter where your study is conducted, our standards, built on decades of regulatory experience and rigorous quality controls, remain constant.

Modeling Excellence: The Crown Bioscience Standard

Crown’s North Carolina facility has been meticulously modeled after our established and highly successful operations in China. This ensures that every procedure, workflow, and standard of quality is fully aligned with the proven, compliant, processes that have made Crown Bioscience a global leader.

Clients working with the North Carolina team can expect:

• Standardized, Compliant Workflows: Every procedure, timeline, and service offering is aligned with our global standards to ensure data consistency and regulatory integrity.
  
  
• Rapid Biobank Access: The North Carolina site now hosts a massive biobank, featuring thousands of PDX models. With new models arriving weekly, these can be revived, thawed, and put into mice on-site, drastically reducing the time required to initiate studies.
  
  
• Operational Readiness: Whether it’s revival from frozen tumor banks, warm passage to maintain model viability, or expansion to grow the biobank, the team is fully equipped to support your preclinical oncology efficacy studies at maximum velocity.

Synergistic Services and Future Growth

While the North Carolina facility is laser-focused on PDX preclinical oncology studies and essential biomarker services, it operates as part of a highly integrated, compliant network.

Currently, on-site services are tailored to support in vivo PDX, with a primary focus on flow cytometry and complete blood counts (CBC). For more complex, downstream requirements, such as histology, Next-Generation Sequencing (NGS), and genomics, the facility collaborates closely with our accredited San Diego site, which houses Crown Bioscience’s most comprehensive biomarker discovery and profiling capabilities.

We are aggressively expanding these capabilities to offer even more robust on-site support in North Carolina. In the coming months, clients can look forward to the addition of:

• ELISA (Enzyme-Linked Immunosorbent Assay)
• MSD (Mesoscale Discovery)
• Expanded CBC capabilities
• Planned LCMS (Liquid Chromatography–Mass Spectrometry) services

At the heart of our work in North Carolina is a shared mission: to impact patient outcomes. From syngeneic models to companion diagnostics and, of course, PDX, Crown Bioscience’s US onshore sites are now better equipped than ever to support every step of the translational pipeline.

Watch the video below to learn more about our North Carolina site.